The medical management of parkinson's disease

Principles of Treatment in Parkinson's Disease

Volumn , Issue , 2005, Pages 119-143

  Schapira, Anthony H V ^a,b   Olanow, C Warren ^c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 42249102675     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7506-5428-9.50010-X     Document Type: Chapter

References (143)

1. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999, 45:577-582.
2. Ponsen MM, Stoffers D, Booij J, Eck-Smit BL, Wolters EC, Berendse HW Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004, 56:173-181.
3. Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002, 125(4):861-870.
4. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24(2):197-211.
5. Mytilineou C, Cohen G Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J Neurochem 1985, 45:1951-1953.
6. Tatton WG, Greenwood CE Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991, 30:666-672.
7. Chiueh CC, Huang SJ, Murphy DL Enhanced hydroxyl radical generation by 2'-methyl analog of MPTP: suppression by clorgyline and deprenyl. Synapse 1992, 11:346-348.
8. + in vivo. Eur J Pharmacol 1993, 243(3):241-247.
9. + toxicity in vivo. Ann NY Acad Sci 2000, 899:255-261.
10. Tatton WG, Ju WY, Holland DP, Tai C, Kwan M (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994, 63:1572-1575.
11. Wadia JS, Chalmers-Redman RM, Ju WJ, Carlile GW, Phillips JL, Fraser AD, et al. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J Neurosci 1998, 18:932-947.
12. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1993, 328:176-183.
13. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995, 38:771-777.
14. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002, 51:604-612.
15. Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. Br Med J 2004, 329:593.
16. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 2002, 326(2):105-108.
17. Maruyama W, Takahashi T, Youdim M, Naoi M The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 2002, 109:467-481.
18. Jenner P Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology 2004, 63(7 Suppl. 2):S13-22.
19. Am OB, Amit T, Youdim MB Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004, 355(3):169-172.
20. Youdim MB, Wadia A, Tatton W, Weinstock M The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 2001, 939:450-458.
21. Parkinson's Study Group A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004, 61:561-566.
22. Rascol O Monoamine oxidase inhibitors: is it time to up the TEMPO?. Lancet Neurol 2003, 2(3):142-143.
23. Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 1994, 657(1/2):207-213.
24. Muralikrishnan D, Mohanakumar KP Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998, 12:905-912.
25. Kondo T, Ito T, Sugita Y Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann NY Acad Sci 1994, 738:222-229.
26. Finotti N, Castagna L, Moretti A, Marzatico F Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol Res 2000, 42(4):287-291.
27. Yoshioka M, Tanaka K, Miyazaki I, Fujita N, Higashi Y, Asanuma M, et al. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci Res 2002, 43(3):259-267.
28. Nishibayashi S, Asanuma M, Kohno M, Gomez-Vargas M, Ogawa N Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem 1996, 67:2208-2211.
29. Gomez-Vargas M, Nishibayashi-Asanuma S, Asanuma M, Kondo Y, Iwata E, Ogawa N Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res 1998, 790(1/2):202-208.
30. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999, 838(1/2):51-59.
31. Clow A, Freestone C, Lewis E, Dexter D, Sandler M, Glover V The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase. Neurosci Lett 1993, 164(1/2):41-43.
32. Kakimura J, Kitamura Y, Takata K, Kohno Y, Nomura Y, Taniguchi T Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur J Pharmacol 2001, 417(1/2):59-67.
33. Gu M, Irvani M, Cooper JM, King D, Jenner P, Schapira AH Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 2004, 91:1075-1081.
34. Jenner P, Iravani MM, Haddon CO, et al. Pramipexole protects against MPTP-induced nigral dopaminergic cell loss in primates. Neurology 2002, 58:494.
35. Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci 1999, 64:1275-1285.
36. Kitamura Y, Kosaka T, Kakimura JI, Matsuoka Y, Kohno Y, Nomura Y, et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1998, 54:1046-1054.
37. 2 and 6-hydroxydopamine. Mov Disord 1998, 13:242-248.
38. Vu TQ, Ling ZD, Ma SY, et al. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J Neural Transm 2000, 107(2):159-176.
39. Takashima H, Tsujihata M, Kishikawa M, Freed WJ Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. Exp Neurol 1999, 159:98-104.
40. Nair VD, Olanow CW, Sealfon SC Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 2003, 373(1):25-32.
41. Sawada H, Ibi M, Kihara T, et al. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 1998, 44:110-119.
42. Parkinson's Study Group Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287:1653-1661.
43. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003, 54:93-101.
44. Schapira AH, Olanow CW Neuroprotection in Parkinson disease:. JAMA 2004, 291:358-364.
45. Ahlskog JE Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003, 60:381-389.
46. Olanow CW A radical hypothesis for neurodegeneration. Trends Neurosci 1993, 16:439-444.
47. Agid Y, Olanow CW, Mizuno Y Levodopa: why the controversy?. Lancet 2002, 360:575.
48. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351:2498-2508.
49. Albin RL, Frey KA Initial agonist treatment of Parkinson disease: a critique. Neurology 2003, 60:390-394.
50. Wooten GF Agonists vs levodopa in PD: the thrilla of whitha. Neurology 2003, 60:360-362.
51. 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002, 59:1541-1550.
52. Rajput AH Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 2001, 8:95-100.
53. Karlsen KH, Tandberg E, Arsland D, Larsen JP Health-related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 2000, 69:584-589.
54. Clarke CE, Zobkiw RM, Gullaksen E Quality of life and care in Parkinson's disease. Br J Clin Pract 1995, 49:288-293.
55. Fahn S Adverse effects of levodopa. The Scientific Basis for the Treatment of Parkinson's Disease 1992, 89-112. Parthenon Publishing Group, Carnforth. C.W. Olanow (Ed.).
56. Contin M, Riva R, Martinelli P A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease. Neurology 1998, 51:1075-1080.
57. Shoulson I, Glaubiger GA, Chase TN On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975, 25:1144-1148.
58. Hardie RJ, Lees AJ, Stern GM On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study. Brain 1984, 107(2):487-506.
59. Mouradian MM, Heuser IJ, Baronti F, Chase TN Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990, 27:18-23.
60. Nutt JG On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987, 22:535-540.
61. Kurth MC, Tetrud JW, Tanner CM, Irwin I, Stebbins GT, Goetz CG, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with "on-off" fluctuations. Neurology 1993, 43:1698-1703.
62. Kostic V, Przedborski S, Flaster E, Sternic N Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991, 41(2 Pt 1):202-205.
63. Olanow CW Single blind double observer-controlled study of carbidopa/levodopa vs bromocriptine in untreated Parkinson patients. Arch Neurol 1988, 45:205.
64. Staal-Schreinemachers AL, Wesseling H, Kamphuis DJ, vd BW, Lakke JP Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study. Neurology 1986, 36:291-293.
65. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 1997, 48:363-368.
66. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998, 55(1):23-30.
67. Barone P, Bravi D, Bermejo-Pareja F, Marconi R, Kulisevsky J, Malagu S, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999, 53:573-579.
68. Parkinson's Disease Study Group Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA 1997, 278:125-130.
69. Shannon KM, Bennett JP, Friedman JH Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 1997, 49:724-728.
70. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 1999, 53:364-370.
71. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997, 49:393-399.
72. Hoehn MM, Elton RL Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 1985, 35:199-206.
73. Toyokura Y, Mizuno Y, Kase M, Sobue I, Kuroiwa Y, Narabayashi H, et al. Effects of bromocriptine on parkinsonism: a nationwide collaborative double-blind study. Acta Neurol Scand 1985, 72(2):157-170.
74. Inzelberg R, Nisipeaunu P, Rabey JM Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996, 47:785-788.
75. Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994, 9:40-47.
76. Diamond SG, Markham CH, Treciokas LJ Double-blind trial of pergolide for Parkinson's disease. Neurology 1985, 35:291-295.
77. Guttman M Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole/Bromocriptine Study Group. Neurology 1997, 49:1060-1065.
78. Lieberman A, Ranhosky A, Korts D Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997, 49:162-168.
79. Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998, 51:1057-1062.
80. Schapira AH Excessive daytime sleepiness in Parkinson's disease. Neurology 2004, 63:S24-27.
81. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004, 61:1044-1053.
82. Muller T, Fritze J Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin Neuropharmacol 2003, 26:109-111.
83. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004, 363:1179-1183.
84. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000, 342:1484-1491.
85. Oertel WH Pergolide versus levodopa (PELMOPET). Mov. Disord 2000, 15(3):4.
86. Parkinson's Disease Study Group Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000, 284:1931-1938.
87. Parkinson's Disease Study Group A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002, 59:1937-1943.
88. Cantello R, Riccio A, Gilli M, Delsedime M, Scarzella L, Aguggia M, et al. Bornaprine vs placebo in Parkinson disease: double-blind controlled cross-over trial in 30 patients. Ital J Neurol Sci 1986, 7(1):139-143.
89. Martin WE, Loewenson RB, Resch JA, Baker AB A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease. Neurology 1974, 24:912-919.
90. Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease: a follow-up study of untreated patients. Brain 1992, 115(6):1701-1725.
91. Friedman JH, Koller WC, Lannon MC, Busenbark K, Swanson-Hyland E, Smith D Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology 1997, 48:1077-1081.
92. Schwab RS, England AC, Poskanzer DC, Young RR Amantadine in the treatment of Parkinson's disease. JAMA 1969, 208:1168-1170.
93. Factor SA, Molho ES Transient benefit of amantadine in Parkinson's disease: the facts about the myth. Mov Disord 1999, 14:515-517.
94. Parkes JD, Baxter RC, Marsden CD, Rees JE Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1974, 37:422-426.
95. Walker JE, Albers JW, Tourtellotte WW, Henderson WG, Potvin AR, Smith A A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson's disease. J Chronic Dis 1972, 25:149-182.
96. Shulman LM, Minagar A, Rabinstein A, Weiner WJ The use of dopamine agonists in very elderly patients with Parkinson's disease. Mov Disord 2000, 15:664-668.
97. Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000, 23:324-330.
98. Parkinson's Disease Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. Arch Neurol 2005, 62:241-248.
99. Poewe WH, Lees AJ, Stern GM Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986, 36:1528-1530.
100. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms: I. Ann Neurol 1988, 24:366-371.
101. Horstink MW, Zijlmans JC, Pasman JW, et al. Which risk factors predict the levodopa response in fluctuating Parkinson's disease?. Ann Neurol 1990, 27:537-543.
102. Roos RA, Vredevoogd CB, van der Velde EA Response fluctuations in Parkinson's disease. Neurology 1990, 40:1344-1346.
103. Koller WC, Hutton JT, Tolosa E, Capilldeo R Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999, 53:1012-1019.
104. Jenner P, Al-Barghouthy G, Smith L, Koupamaki M, Jackson M Entacapone combined with L-dopa enhances antiparkinsonian activity and avoids dyskinesia in the MPTP-treated primate model of Parkinson's disease. Mov Disord 2002, 17(5):S57-58.
105. Sage JI, Trooskin S, Sonsalla PK, et al. Experience with continuous enteral levodopa infusions in the treatment of 9 patients with advanced Parkinson's disease. Neurology 1989, 39(11 Suppl. 2):60-63. discussion 72-73.
106. Stocchi F, Ruggieri S, Vacca L, Olanow CW Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002, 125:2058-2066.
107. Stocchi F, Vacca L, Berardelli A, Onofrj M, Manfredi M, Ruggieri S Dual dopamine agonist treatment in Parkinson's disease. J Neurol 2003, 250:822-826.
108. Rinne UK, Larsen JP, Siden A, Worm-Petersen J Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998, 51:1309-1314.
109. Russ H, Muller T, Woitalla D, Rahbar A, Hahn J, Kuhn W Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch Pharmacol 1999, 360:719-720.
110. Hauser RA, Molho E, Shale H, Pedder S, Dorflinger EE A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. Mov Disord 1998, 13:643-647.
111. Jorga KM COMT inhibitors: pharmacokinetic and pharmacodynamic comparisons. Clin Neuropharmacol 1998, 21:S9-16. (Suppl.).
112. Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR Tolcapone and fulminant hepatitis. Lancet 1998, 352:958.
113. Korlipara LV, Cooper JM, Schapira AH Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone, to cultured human neuroblastoma cells. Neuropharmacology 2004, 46:562-569.
114. Tasmar [package insert] 1998, Roche Laboratories Inc., Nutley, NJ.
115. Marco AD, Appiah-Kubi LS, Chaudhuri KR Use of the dopamine agonist cabergoline in the treatment of movement disorders. Expert Opin Pharmacother 2002, 3:1481-1487.
116. Lhermitte F, Agid Y, Signoret JL Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol 1978, 35:261-263.
117. Verhagen ML, Del Dotto P, van den MP, Fang J, Mouradian MM, Chase TN Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998, 50:1323-1326.
118. Metman LV, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998, 50:1323-1326.
119. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999, 56:1383-1386.
120. Snow BJ, Macdonald L, Mcauley D, Wallis W The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000, 23:82-85.
121. Hely MA, Morris JG, Reid WG, Trafficante R Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005, 20(2):190-199.
122. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000, 11(2):58-65.
123. Rektorova I, Rektor I, Bares M, Dostal V, Ehler E, Fanfrdlova Z, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003, 10(4):399-406.
124. Pollak P, Tison F, Rascol O, Destee A, Pere JJ, Senard JM, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004, 75:689-695.
125. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003, 18:510-514.
126. Mancini F, Tassorelli C, Martignoni E, Moglia A, Nappi G, Cristina S, et al. Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease. Clin Neuropharmacol 2004, 27:33-37.
127. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004, 351:2509-2518.
128. Jellinger KA Pathology of Parkinson's disease: changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991, 14:153-197.
129. Lees AJ, Blackburn NA, Campbell VL The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988, 11:512-519.
130. van Hilten B, Hoff JI, Middelkoop HA, van der Velde EA, Kerkhof GA, Wauquier A, et al. Sleep disruption in Parkinson's disease: assessment by continuous activity monitoring. Arch Neurol 1994, 51:922-928.
131. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003, 18:659-667.
132. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002, 287:455-463.
133. Happe S, Pirker W, Sauter C, Klosch G, Zeitlhofer J Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil. J Neurol 2001, 248:632-634.
134. Basson R Sex and idiopathic Parkinson's disease. Adv Neurol 2001, 86:295-300.
135. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001, 71:371-374.
136. Raffaele R, Vecchio I, Giammusso B, Morgia G, Brunetto MB, Rampello L Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol 2002, 41(4):382-386.
137. O'sullivan JD Apomorphine as an alternative to sildenafil in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002, 72:681.
138. Stocchi F, Carbone A, Inghilleri M, Monge A, Ruggieri S, Berardelli A, et al. Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 1997, 62:507-511.
139. Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003, 18:685-688.
140. Marsden CD Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994, 17(2):S32-44.
141. Rabinstein AA, Shulman LM Management of behavioral and psychiatric problems in Parkinson's disease. Parkinsonism Relat Disord 2001, 7:41-50.
142. Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC Pain in Parkinson's disease. Mov Disord 1986, 1:45-49.
143. Hillen ME, Sage JI Nonmotor fluctuations in patients with Parkinson's disease. Neurology 1996, 47:1180-1183.